These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 21322567)

  • 1. Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors.
    Leproult E; Barluenga S; Moras D; Wurtz JM; Winssinger N
    J Med Chem; 2011 Mar; 54(5):1347-55. PubMed ID: 21322567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling.
    Gunby RH; Ahmed S; Sottocornola R; Gasser M; Redaelli S; Mologni L; Tartari CJ; Belloni V; Gambacorti-Passerini C; Scapozza L
    J Med Chem; 2006 Sep; 49(19):5759-68. PubMed ID: 16970400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies.
    Gambacorti-Passerini C; Gasser M; Ahmed S; Assouline S; Scapozza L
    Leukemia; 2005 Jul; 19(7):1267-9. PubMed ID: 15858616
    [No Abstract]   [Full Text] [Related]  

  • 4. The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl.
    Eck MJ; Manley PW
    Curr Opin Cell Biol; 2009 Apr; 21(2):288-95. PubMed ID: 19217274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine kinase inhibition: Ligand binding and conformational change in c-Kit and c-Abl.
    Healy EF; Johnson S; Hauser CR; King PJ
    FEBS Lett; 2009 Sep; 583(17):2899-906. PubMed ID: 19660459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and docking study of 2-phenylaminopyrimidine Abl tyrosine kinase inhibitors.
    Lü S; Luo Q; Hao X; Li X; Ji L; Zheng W; Wang F
    Bioorg Med Chem Lett; 2011 Dec; 21(23):6964-8. PubMed ID: 22033461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases.
    Singh J; Dobrusin EM; Fry DW; Haske T; Whitty A; McNamara DJ
    J Med Chem; 1997 Mar; 40(7):1130-5. PubMed ID: 9089334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis.
    Raafat A; Zoltan-Jones A; Strizzi L; Bargo S; Kimura K; Salomon D; Callahan R
    Oncogene; 2007 Feb; 26(5):662-72. PubMed ID: 16878155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding.
    Bogoyevitch MA; Fairlie DP
    Drug Discov Today; 2007 Aug; 12(15-16):622-33. PubMed ID: 17706543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
    Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
    J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty.
    Seeliger MA; Nagar B; Frank F; Cao X; Henderson MN; Kuriyan J
    Structure; 2007 Mar; 15(3):299-311. PubMed ID: 17355866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
    Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
    Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steered molecular dynamics simulations reveal the likelier dissociation pathway of imatinib from its targeting kinases c-Kit and Abl.
    Yang LJ; Zou J; Xie HZ; Li LL; Wei YQ; Yang SY
    PLoS One; 2009 Dec; 4(12):e8470. PubMed ID: 20041122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.
    Mahboobi S; Dove S; Sellmer A; Winkler M; Eichhorn E; Pongratz H; Ciossek T; Baer T; Maier T; Beckers T
    J Med Chem; 2009 Apr; 52(8):2265-79. PubMed ID: 19301902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors.
    Mol CD; Fabbro D; Hosfield DJ
    Curr Opin Drug Discov Devel; 2004 Sep; 7(5):639-48. PubMed ID: 15503866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
    Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
    Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.
    Schmandt RE; Broaddus R; Lu KH; Shvartsman H; Thornton A; Malpica A; Sun C; Bodurka DC; Gershenson DM
    Cancer; 2003 Aug; 98(4):758-64. PubMed ID: 12910520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A minimalist approach to fragment-based ligand design using common rings and linkers: application to kinase inhibitors.
    Aronov AM; Bemis GW
    Proteins; 2004 Oct; 57(1):36-50. PubMed ID: 15326593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of compound 584, an Abl kinase inhibitor with lasting effects.
    Puttini M; Redaelli S; Moretti L; Brussolo S; Gunby RH; Mologni L; Marchesi E; Cleris L; Donella-Deana A; Drueckes P; Sala E; Lucchini V; Kubbutat M; Formelli F; Zambon A; Scapozza L; Gambacorti-Passerini C
    Haematologica; 2008 May; 93(5):653-61. PubMed ID: 18367480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural biology contributions to tyrosine kinase drug discovery.
    Cowan-Jacob SW; Möbitz H; Fabbro D
    Curr Opin Cell Biol; 2009 Apr; 21(2):280-7. PubMed ID: 19208462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.